Budget Amount *help |
¥45,630,000 (Direct Cost: ¥35,100,000、Indirect Cost: ¥10,530,000)
Fiscal Year 2022: ¥13,130,000 (Direct Cost: ¥10,100,000、Indirect Cost: ¥3,030,000)
Fiscal Year 2021: ¥13,130,000 (Direct Cost: ¥10,100,000、Indirect Cost: ¥3,030,000)
Fiscal Year 2020: ¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
|
Outline of Final Research Achievements |
p16-positive senescent-like stromal cells in cancer tissue functioned in an inhibitory manner against tumor immunity and were strongly involved in tumor growth by promoting cancer invasion and metastasis, as well as tumor fibrosis. Indeed, removal of p16-positive senescent-like stromal cells significantly reduced tumor growth and markedly improved the fibrosis seen in the central region. Furthermore, removal of p16-positive senescent-like stromal cells inhibited tumor growth more strongly than did administration of anticancer agents, and when combined with anticancer agents, the effect was additive in inhibiting tumor growth.
|